Noboru Nakaigawa

ORCID

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 8

Top Venues

BMC cancer

Cancer chemotherapy and pharmacology

Clinical & experimental metastasis

BMC urology

This page only lists publications with an associated author ORCID identifier.

Publications

Go Noguchi, Noboru Nakaigawa, Susumu Umemoto, Kota Kobayashi, Yosuke Shibata, Sohgo Tsutsumi, Masato Yasui, Shinji Ohtake, Takahisa Suzuki, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Keiichi Kondo, Yuka Igarashi, Tetsuro Sasada, Takeshi Kishida, Masahiro Yao
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer chemotherapy and pharmacology 86 (1) (2020)
Tadashi Tabei, Noboru Nakaigawa, Tomohiro Kaneta, Ichiro Ikeda, Keiichi Kondo, Kazuhide Makiyama, Hisashi Hasumi, Narihiko Hayashi, Takashi Kawahara, Koji Izumi, Kimito Osaka, Kentaro Muraoka, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura, Kazuki Kobayashi, Tomio Inoue, Masahiro Yao
Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC cancer 19 (1) (2019)
Noboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, Ukihide Tateishi, Ryogo Minamimoto, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Koji Izumi, Takashi Kawahara, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura, Tomio Inoue, Masahiro Yao
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. Cancer chemotherapy and pharmacology 81 (4) (2018)
Shinji Ohtake, Takashi Kawahara, Go Noguchi, Noboru Nakaigawa, Kimio Chiba, Hiroji Uemura, Masahiro Yao, Kazuhide Makiyama
Renal Cell Carcinoma in a Horseshoe Kidney Treated with Laparoscopic Partial Nephrectomy. Case reports in oncological medicine 2018 (2018)
Takashi Kawahara, Yukari Ishiguro, Shinji Ohtake, Ikuma Kato, Yusuke Ito, Hiroki Ito, Kazuhide Makiyama, Keiichi Kondo, Yasuhide Miyoshi, Yasushi Yumura, Narihiko Hayashi, Hisashi Hasumi, Kimito Osaka, Kentaro Muraoka, Koji Izumi, Jun-Ichi Teranishi, Hiroji Uemura, Masahiro Yao, Noboru Nakaigawa
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC urology 18 (1) (2018)
Go Noguchi, Noboru Nakaigawa, Masataka Taguri, Sohgo Tsutsumi, Yoko Saito, Sachi Fukui, Masato Yasui, Takashi Tokita, Taku Mitome, Tomoyuki Tatenuma, Shinnosuke Kuroda, Koichi Abe, Daiki Ueno, Kazuhiro Namura, Susumu Umemoto, Akitoshi Takizawa, Junichi Ohta, Teiichiro Ueki, Takeshi Watanabe, Kazuki Kobayashi, Keiichi Kondo, Takeshi Kishida, Hitomi Kanno, Kazuo Kitami, Takeharu Yamanaka, Masahiro Yao
Time-dependent change in relapse sites of renal cell carcinoma after curative surgery. Clinical & experimental metastasis 35 (1-2) (2018)
Ryo Kasahara, Takashi Kawahara, Shinji Ohtake, Yoko Saitoh, Sohgo Tsutsumi, Jun-Ichi Teranishi, Yasuhide Miyoshi, Noboru Nakaigawa, Masahiro Yao, Kazuki Kobayashi, Hiroji Uemura
A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed research international 2017 (2017)
Noboru Nakaigawa, Keiichi Kondo, Daiki Ueno, Kazuhiro Namura, Kazuhide Makiyama, Kazuki Kobayashi, Koichi Shioi, Ichiro Ikeda, Takeshi Kishida, Tomohiro Kaneta, Ryogo Minamimoto, Ukihide Tateishi, Tomio Inoue, Masahiro Yao
The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. BMC cancer 17 (1) (2017)

Noboru Nakaigawa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Noboru Nakaigawa